Ovarian cancer is the fifth most prevalent cancer among women and is the leading cause of gynecological cancer fatalities in the US. Because there are often no signs of ovarian cancer until the disease has progressed to an advanced stage, identifying sensitive and specific early detection biomarkers is of paramount importance. To address this need, this proposal will apply a new cutting-edge approach called “adductomics” to investigate candidate biomarkers for early ovarian cancer detection. While protein adducts (addition products) have been used for decades as exposure biomarkers, they have been neglected in discovery-based experiments as early diagnostic biomarkers for cancer.
|Effective start/end date
|1/1/14 → 12/31/15
- Northwestern Memorial Hospital (Exhibit B.9)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.